Acumen Pharmaceuticals, Inc. reports termination of material agreement

Acumen Pharmaceuticals, Inc. filed an 8-K covering termination of a material definitive agreement and SEC Item 2.05. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.